Fresenius Kabi is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $18.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Fresenius Kabi's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Otulfi |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved 27 Sep 2024; launched 3 Mar 2025; interchangeable | $6.1B |
| Prolia Conexxence |
Amgen | Biosimilar | 2025 | FDA-approved 25 Mar 2025; launched Jul 2025; interchangeable | $4.4B |
| Xgeva Bomyntra |
Amgen | Biosimilar | 2025 | FDA-approved 25 Mar 2025; launched Jul 2025; interchangeable | $2.1B |
| Entyvio PB016 |
Takeda | Biosimilar | 2032 | Filed with the FDA Jul 2026; in litigation, sued Aug 2026. FDA accepted the filing in Jul 2026 | ≈$6.0B |
Company facts: Fresenius. Each drug page lists sources for these entries. Brand sales show the size of the market, not Fresenius Kabi's share of it.
Fresenius Kabi sells US copies of 3 of these drugs: Stelara (since 3 Mar 2025), Prolia (since Jul 2025) and Xgeva (since Jul 2025). It also has applications filed for Entyvio. It has is in court over 1. Of the 70 makers we follow, 21 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.